Using the previously published PGC‐1α inhibitor SR‐18292 (data not shown), we did not observe relevant effects in GB cell lines which contrasts published data demonstrating the inhibitor's efficacy in other models, such as cholangiocarcinoma cell models,56 suggesting a differential regulation in GB. Here, PPARGC1A is linked to cholangiocarcinoma.